Diabetes (types 1 and 2) - long acting insulin analogues
The clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes
Summary
NICE has recommended insulin glargine as an option for people with type 1 diabetes. For people with type 2 diabetes who need to take insulin, NICE has recommended that insulin glargine should be an option only if the person: needs help with his or her insulin injections from a carer or healthcar ...
The recommendations in this technology appraisal relating to type 2 diabetes have been replaced by recommendations in the Diabetes - type 2 (update) clinical guideline published in May 2008. Please note that the recommendations in this technology appraisal relating to type 1 diabetes have not changed.
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in November 2005
About this guidance
Technology appraisals TA53
Issued: December 2002
How this guidance was produced